MedTrace Logo

Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension

NCT00240656 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2008-06-30

No results posted yet for this study

Summary

The purpose of this study is to determine whether a larger dose of the aldosterone antagonist spironolactone combined with an ACE inhibitor (captopril) and a beta-blocker (carvedilol) is effective in reverse pulmonary artery remodeling in patients with pulmonary arterial hypertension (PAH)secondary to congenital heart disease

Conditions

  • Hypertension, Pulmonary

Interventions

DRUG

spironolactone captopril carvedilol

Sponsors & Collaborators

  • Hebei Medical University

    lead OTHER

Principal Investigators

  • Kunshen Liu, M.D. · The First Hospital of Hebei Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Completion
2006-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00240656 on ClinicalTrials.gov